GSK Raises Annual Outlook After Shingles Vaccine Helps Boost Q3 Results
By Scott Kanowsky
Investing.com -- Shares in GlaxoSmithKline (LON:GSK) moved higher on Wednesday after the drugmaker lifted its full-year earnings and sales outlook following better-than-expected third-quarter results.
The U.K.-based group now expects adjusted operating profit to increase between 15%-17% in 2022, while revenue, excluding pandemic-related sales, is seen rising by 8%-10%.
It had previously guided for an income leap of 13%-15% on revenue growth of 6%-8%.
The move comes after GSK posted turnover of £7.83 billion in the third quarter - an expansion of 9% compared to the corresponding period last year - driven in part by record demand for its Shingrix shingles vaccine.
GSK's specialty medicines division also reported quarterly sales of £2.75 billion, a 24% year-on-year jump, thanks to strong performance of its COVID-19 medicine Xevudy.
Adjusted operating profit during the three months to September 30 climbed by 4% to £2.6 billion.
"We are again raising our full-year guidance and expect good momentum in 2023, further strengthening our confidence in our performance outlooks," said chief executive officer Emma Walmsley in a statement.
She added that the firm is making "good progress" in strengthening its drug pipeline and will continue to "invest in targeted business development."
Related Articles
GSK Raises Annual Outlook After Shingles Vaccine Helps Boost Q3 Results
Wall St opens lower with focus on Fed rate decision
Analysts Note a 'Tough' Quarter for Paramount, Shares Down 9%
